Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
IlDong Pharmaceutical Co Ltd
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03604016CT.gov Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis B Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Besifovir Dipivoxil (this asset) | IlDong Pharmaceutical Co Ltd | Approved | BB · 65 |
| Entecavir | Sun Yat-sen University | P4 | BBB |
| Lamivudine | Fudan University | P4 | BBB |
| Tenofovir | Ruijin Hospital | P4 | BB |
| Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester | West China Hospital | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Tenofovir Alafenamide | Sun Yat-sen University | P4 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
+34 more in the Hepatitis B Virus Infection cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Besifovir Dipivoxil in Hepatitis B Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/besifovir-dipivoxil-hepatitis-b-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →